Imagine being able to answer your product’s most challenging safety & effectiveness questions before you even recruit clinical trial participants.
The key is in our genes.
Genetic technologies are evolving, with significant impact on the pharma & biotech industry.
Don Gabriel, MD, PhD, serves as UBC’s consultant Senior Director of Medical Oncology & Scientific Strategy. He is a nationally recognized oncology hematologist with more than 30 years of experience.
Scroll down & let Dr. Don take you on an educational tour of how these technologies are impacting every phase of the product lifecycle.
Genetics has been estimated to account for anywhere between 20% & 95% of the variation in individual responses to medications.1
The good news: We’re getting smarter with how we treat diseases through something called pharmacogenomics.
So, what is pharmacogenomics?
It’s the study of individuals’ genetic variations & how that impacts the way people respond to medications.
Education is necessary to put this principle into practice.
Patients look to nurses & physicians for guidance while undergoing personalized therapies.
Those physicians & nurses need the right information & tools to realize the benefits of pharmacogenomics.
REFERENCE: 1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144–1153. | Article | PubMed | ISI | CAS |